Perfil del Médico Especialista

Dr. Roberto Iván López

Oncología

Facultad de Medicina, Universidad Nacional De Panamá
Años de Experiencia: 36

FACULTAD DE ESTUDIOS:

Facultad de Medicina, Universidad Nacional De Panamá

RESIDENCIA DE ESTUDIOS:

Beatson Oncology Centre, Glasgow, U K

MIEMBRO DE:

ASCO: American Society of Clinical Oncology
ESMO: European Society of Medical Oncology
SPO: Sociedad Panameña de Oncología
IASLC: International Asociation for Study of Lung Cancer
LACOG: Latin American Cooperative Oncology Group

CERTIFICACIONES:

ESMO certification

EXPERIENCIA LABORAL:

2005 a la fecha: Jefe Titular del Servicio de Oncología Médica del Instituto Oncológico Nacional (ION)
2007 a la fecha: Jefe del Departamento de Servicios Clínicos del ION
2006 a l fecha: Director Médico, Centro Oncológico Punta Pacífica
2004 - 2006 Director de Docencia e Investigación del ION
1995 a la fecha: Oncólogo Médico, Instituto Oncológico Nacional (ION)

Investigador Principal en los siguientes estudios:

R26; Protocol HERA: R20;A randomized three arm multi-centre comparison of 1 year and 2 years of Herceptin versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapyR21;

R26; Protocol RHEA R20;R20;Phase II study of Herceptin, alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cacer, who have relapsed after receiving Herceptin in the adjuvant setting for HER2 positive early breast cance
R26;

R26; Protocol AVANT R20;: A multinational fase III, randomized three arm studyfo Bevacizumab (q3w o q2w) combined with capecitabine and intermitent oxaliplatin (Xelox) or Fluorouracil plus leucovorine with oxaliplatin (Folfox 4) vs Folfox 4 chemotherapy alone, in adjuvant Colon carcinoma.

R26; Protocol AVADO R20;A multicentric randomized , double blind, placebo controled study to assess the efficacy and safety of bevacizumab combined with docetaxel vs docetaxel plus placebo, as a first line treatment in metastatic breast cancer, HER 2 negative patients.R21;

R26; Protocol TOGA R20;An open label randomized multicentre phase III study of trastuzumab in combinations with a fluorapyramidine and cisplatin versus chemoterapy alone as first line therapy in patients with HER2 positivie advanced gastric cancer.

R26; Protocol Colon adj : An open label randomized phase III Stuyd of iintermittent oral Capacitabine in combination with Oxaliplatin (Q3W) (Xelox) versus fluorouracil/leucovorin as adyuvant therapy for patients who have undergone surgery dor colon carcinoma, ajcc/uicc stage III (Dukes Stages C)

R26; Protocol R20;Bone PainR21; A randomized three arm study, double dummy, placebo controlled, comparing the efficacy of intravenous doses of impregnation followed by a maintenance oral Ibandronic acid versus zoledrónic acid, in patients with bone metastasis and moderate to severe pain.

R26; Protocol BO22227: R20;A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) Trastuzumab with intravenous (IV) Trastuzumab administered in women with HER2 positive early breast cancer (EBC)R21;

R26; Protocolo D0810C00041: A phase II, open-label, randomized, comparative, multicentre study to compare the efficacy and tolerability of Olaparib in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin alone in patient with Platinum sensitive advanced serous ovarian cancer.

R26; Protocol D0102C00003: A phase I / II multicentre study of AZD8931 in combination with weekly Paclitaxel to assess the safety, tolerability, Pharmacokinetics and efficacy in patient with advanced solid tumours and in a selected population with low HER2-expressing locally recurrent and / or metastatic breast cancer (THYME).

R26; Protocol 1199.14: Multicentre, double-blind, phase III trial to investigate de efficacy and safety of oral BIBF1120 plus standard Pemetrexed therapy compared to placebo plus standard Pemetrexed therapy in patient with satge IIIB/IV or recurrent NSCLC after failure of first-line chemotherapy.

Panamá, Ciudad de Panamá
204-8000
rilopez@cwpanama.net

Ubicación